-
Posted by
Two Blokes Apr 17 -
Filed in
Stock
-
2 views
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
